诚意药业（603811）8月14日主力资金净流出3363.08万元

Group 1 - The core viewpoint of the article highlights the financial performance and stock market activity of Chengyi Pharmaceutical Co., Ltd. as of August 14, 2025, showing a decline in stock price and significant net outflow of funds [1] - Chengyi Pharmaceutical reported total revenue of 186 million yuan for Q1 2025, representing a year-on-year growth of 21.26%, and a net profit attributable to shareholders of 45.79 million yuan, up 40.10% year-on-year [1] - The company's liquidity ratios are strong, with a current ratio of 1.565 and a quick ratio of 1.042, alongside a low debt-to-asset ratio of 22.38% [1] Group 2 - Chengyi Pharmaceutical has made investments in 8 companies and participated in 3,615 bidding projects, indicating active engagement in business expansion [2] - The company holds 78 trademark registrations and 43 patents, showcasing its commitment to intellectual property and innovation [2] - Additionally, Chengyi Pharmaceutical possesses 283 administrative licenses, reflecting its compliance and operational capabilities within the pharmaceutical industry [2]